Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
Abstract Background Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-024-04442-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572012663406592 |
|---|---|
| author | Xiaoyan Liang Jianghong Dai Feifei Wang |
| author_facet | Xiaoyan Liang Jianghong Dai Feifei Wang |
| author_sort | Xiaoyan Liang |
| collection | DOAJ |
| description | Abstract Background Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents. In this analysis, we aimed to compare the risk of AF in patients with T2DM who were treated with SGLT-2 inhibitors versus DPP-4 inhibitors. Methods Relevant publications comparing AF in patients with T2DM treated by SGLT-2 inhibitors versus DPP-4 inhibitors were searched through electronic databases. AF was the clinical endpoint in this analysis. Revman 5.4 software was used to carry out this analysis. Risk ratios (RR) with 95% confidence intervals (CIs) were used to assess the outcome. Results Eleven studies with a total number of 1,019,476 participants with T2DM were included in this analysis whereby 480,549 patients were assigned to SGLT-2 inhibitors and 538,927 patients were assigned to DPP-4 inhibitors. Result of this analysis showed SGLT-2 inhibitors to be associated with a significantly lower risk of AF compared to DPP-4 inhibitors in these patients with T2DM (RR: 0.57, 95% CI: 0.39 – 0.85; P = 0.006). Conclusions Based on the result of this analysis, the risk of AF was significantly reduced with SGLT-2 inhibitors when compared to DPP-4 inhibitors in these patients with T2DM. This hypothesis should be confirmed in future larger studies. |
| format | Article |
| id | doaj-art-84233be5cda3451d903220b0a2d33164 |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-84233be5cda3451d903220b0a2d331642025-02-02T12:07:46ZengBMCBMC Cardiovascular Disorders1471-22612025-01-012511910.1186/s12872-024-04442-5Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysisXiaoyan Liang0Jianghong Dai1Feifei Wang2School of Public Health, Xinjiang Medical UniversityDepartment of Epidemiology and Biostatistics, School of Public Health, Xinjiang Medical UniversityThe second Affiliated Hospital of Xi’an Jiaotong University, Xinjiang Hospital (People’s Hospital of Xinjiang Uygur Autonomous Region, Bainiaohu Hospital)Abstract Background Several studies showed higher risks of cardiovascular complications to have been observed in patients with type 2 diabetes mellitus (T2DM). Atrial fibrillation (AF) and atrial flutter have been more pronounced in patients with hyperglycemia. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are now considered as second-line treatment for patients with T2DM following inadequate glycemic control with first line agents. In this analysis, we aimed to compare the risk of AF in patients with T2DM who were treated with SGLT-2 inhibitors versus DPP-4 inhibitors. Methods Relevant publications comparing AF in patients with T2DM treated by SGLT-2 inhibitors versus DPP-4 inhibitors were searched through electronic databases. AF was the clinical endpoint in this analysis. Revman 5.4 software was used to carry out this analysis. Risk ratios (RR) with 95% confidence intervals (CIs) were used to assess the outcome. Results Eleven studies with a total number of 1,019,476 participants with T2DM were included in this analysis whereby 480,549 patients were assigned to SGLT-2 inhibitors and 538,927 patients were assigned to DPP-4 inhibitors. Result of this analysis showed SGLT-2 inhibitors to be associated with a significantly lower risk of AF compared to DPP-4 inhibitors in these patients with T2DM (RR: 0.57, 95% CI: 0.39 – 0.85; P = 0.006). Conclusions Based on the result of this analysis, the risk of AF was significantly reduced with SGLT-2 inhibitors when compared to DPP-4 inhibitors in these patients with T2DM. This hypothesis should be confirmed in future larger studies.https://doi.org/10.1186/s12872-024-04442-5Atrial fibrillationType 2 diabetes mellitusSGLT-2 inhibitorsDPP-4 inhibitors |
| spellingShingle | Xiaoyan Liang Jianghong Dai Feifei Wang Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis BMC Cardiovascular Disorders Atrial fibrillation Type 2 diabetes mellitus SGLT-2 inhibitors DPP-4 inhibitors |
| title | Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis |
| title_full | Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis |
| title_fullStr | Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis |
| title_full_unstemmed | Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis |
| title_short | Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis |
| title_sort | sodium glucose co transporter 2 sglt2 inhibitors versus dipeptidyl peptidase 4 dpp 4 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes mellitus a meta analysis |
| topic | Atrial fibrillation Type 2 diabetes mellitus SGLT-2 inhibitors DPP-4 inhibitors |
| url | https://doi.org/10.1186/s12872-024-04442-5 |
| work_keys_str_mv | AT xiaoyanliang sodiumglucosecotransporter2sglt2inhibitorsversusdipeptidylpeptidase4dpp4inhibitorsandtheriskofatrialfibrillationinpatientswithtype2diabetesmellitusametaanalysis AT jianghongdai sodiumglucosecotransporter2sglt2inhibitorsversusdipeptidylpeptidase4dpp4inhibitorsandtheriskofatrialfibrillationinpatientswithtype2diabetesmellitusametaanalysis AT feifeiwang sodiumglucosecotransporter2sglt2inhibitorsversusdipeptidylpeptidase4dpp4inhibitorsandtheriskofatrialfibrillationinpatientswithtype2diabetesmellitusametaanalysis |